Latest news and press releases about Oragenics, Inc. (OGEN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option.
Price
| Price | $0.50 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.61 |
| EV / EBITDA | 0.22 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -144.23% |
| Return on Invested Capital | -279.54% |
| Return on Assets | -183.59% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AIM · CANF · CNSP · ENSC · KALA · KZIA · QLGN
Explore sector: Healthcare · Biotechnology
More sections of OGEN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks